• Skip to primary navigation
  • Skip to main content
  • Skip to footer

LKT Labs

Biochemicals for Life Science Research

  • Products
    • New Products
    • Cancer Biology
    • Cardiovascular
    • Endocrine Signaling and Immunology
    • Metabolic and GI Pathology
    • Microbiology
    • Natural Products
    • Neuroscience
    • Peptides
    • Pharmaceutical Impurities and Derivatives
    • Stem Cell Modulators
  • Services
    • Custom Synthesis
    • Natural Product Isolation
    • Analytical Services
  • Int’l Distributors
  • Support
    • About LKT Labs
    • General Inquiry
    • Bulk Quote Request
    • Document Request
    • Technical Support
    • Catalog Request
    • Product Flyers
  • Contact Us
  • Cart
  • Login / Register
Omeprazole Impurity F and G mixture

Omeprazole Impurity F and G mixture

Product ID O486188
Cas No. 125656-82-8, 125656-83-9
Purity ≥98%
Product Unit SizeCostQuantityStock
1 mg $118.00 In stock
5 mg $355.00 In stock
25 mg $1,021.00 In stock
Bulk Quote

Quicklinks

  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Custom Order

Description

Omeprazole Impurity F and G mixture is a mixture of the regioisomers omeprazole related compounds 8(9)-Methoxy-1,3-dimethyl-12-thioxopyrido[1’,2’:3,4]imidazo[1,2-a]benzimidazol-2-(12H) -one.

Omeprazole is a proton pump inhibitor (PPI) that acts as an antagonist at H+/K+ ATPases and is clinically used to treat gastroesophageal reflux disease (GERD), dyspepsia, and peptic ulcer disease. Omeprazole exhibits antacid, anti-ulcerative, and anti-diabetic activities; it also inhibits the mitochondrial carnitine/acylcarnitine transporter. Omeprazole decreases blood glucose levels and Hb1Ac, improves glucose tolerance, and induces β cell neogenesis and activation.

Product Info

Cas No.

125656-82-8, 125656-83-9

Purity

≥98%

Formula

C16H13N3O2S

Formula Wt.

311.4

Chemical Name

8-methoxy-1,3-dimethyl-12-thioxobenzo[4',5']imidazo[2',1':2,3]imidazo[1,5-a]pyridin-2(12H)-one compound with 9-methoxy-1,3-dimethyl-12-thioxobenzo[4',5']imidazo[2',1':2,3]imidazo[1,5-a]pyridin-2(12H)-one (1:1)

Synonym

Omeprazole Related Compound F and G mixture; Omeprazole EP Impurity F and G mixture.

Solubility

Soluble in ethanol or methanol. Slightly soluble in acetone, isopropanol, or water.

Shipping and Storage

Store Temp

-80°C

Ship Temp

Ambient

Downloads

Info Sheet

O486188 Info Sheet PDF

References

Tonazzi A, Eberini I, Indiveri C. Molecular mechanism of inhibition of the mitochondrial carnitine/acylcarnitine transporter by omeprazole revealed by proteoliposome assay, mutagenesis and bioinformatics. PLoS One. 2013 Dec 9;8(12):e82286. PMID: 24349247.

Ward RM, Kearns GL. Proton pump inhibitors in pediatrics : mechanism of action, pharmacokinetics, pharmacogenetics, and pharmacodynamics. Paediatr Drugs. 2013 Apr;15(2):119-31. PMID: 23512128.

Mefford IN, Mefford JT, Burris CA. Improved diabetes control and pancreatic function in a type 2 diabetic after omeprazole administration. Case Rep Endocrinol. 2012;2012:468609. PMID: 22937295.

Custom Order

  • Size of single unit expressed as number (e.g. '500' in the case of 500 mg)
  • Total quantity of unit size desired (e.g. '10' in the case of 10 x 500 mg). If only one unit is desired, you may leave this blank.
  • This field is for validation purposes and should be left unchanged.

Related Products

  • A7034

    Aripiprazole

    D2 and 5-HT1A partial agonist, 5-HT2C/6/7 antag...

    ≥98%
  • G0000

    G250.A2 Peptide

    Peptide, carbonic anhydrase G250 epitope.

    ≥95%
  • V0269

    Vardenafil Dihydrochloride

    PDE5 inhibitor.

    ≥99%
  • B8072

    3-tert-Butyl-5-Methoxycatechol

    BHA derivative, cellular differentiation induce...

    ≥95%
  • C2916

    Chenodeoxycholic Acid

    Endogenous bile acid; FXR agonist.

    ≥98%
  • E7556

    Etodolac

    NSAID; TRPA1 agonist, COX-2 inhibitor.

    ≥98%
  • T5761

    Topotecan Hydrochloride

    Captothecin derivative; topoisomerase I inhibit...

    ≥97%
  • H9802

    Hyaluronic Acid Sodium (7-10 kDA)

    Glycosaminoglycan

  • F4432

    FLI-06

    Notch inhibitor.

    ≥99%
  • S7618

    StemRegenin 1 Hydrochloride

    AhR antagonist.

    ≥98%
  • F5968

    Foretinib

    ROS1, MET, Ron, Axl, TIE-2, VEGFR2 inhibitor.

    ≥98%
  • G3254

    10-Gingerol

    Phenol found in Zingiber; 5-HT3 antagonist.

    ≥99%
  • T3584

    Tivantinib

    MET and GSK-3α/β inhibitor.

    ≥98%
  • P2516

    S-(N-Phenylbutylthiocarbamoyl)-L-cysteine

    Cysteine-ITC conjugate, antioxidant.

    ≥98%
  • T0093

    2′-Acetyltaxol

    Taxane synthesis intermediate.

    ≥98%
  • D5746

    Dolasetron

    5-HT3 antagonist.

    ≥98%
  • B6998

    Bryostatin 1

    Macrolide lactone found in Bugula; TLR4 activat...

    ≥98%
  • P7218

    Pseudoprotodioscin

    Steroidal saponin found in Tribulus, Trigonella...

    ≥98%
  • X1854

    p-Xyleneselenocyanate

    Synthetic derivative of selenocyanate.

    ≥99%
  • D0005

    Dabrafenib Mesylate

    B-Raf and c-Raf inhibitor.

    ≥98%

Footer

  • Contact Us
  • About Us
  • Site Map
  • Terms and Conditions
LKT Laboratories, Inc.
545 Phalen Blvd.
St. Paul MN, 55130

Ph: (888)-558-5227
Fax: (888)-558-7329

©2026 LKT Laboratories, All Rights Reserved - Products for research use only